Rare Cell Isolation Market Grows with Single-Cell Analysis Demand

In 2023, the global rare cell isolation market was valued at USD 1.83 billion, and it is forecast to grow to USD 3.46 billion by 2030, representing a compound annual growth rate (CAGR) of 9.71 % from 2024 to 2030. The market expansion is largely driven by advances in biotechnology and the rising demand for precision medicine.

Key Market Trends & Insights

• In 2023, North America led the market with a share of 40.26 %.
• The Asia Pacific market is expected to expand at the fastest pace, with a projected CAGR of 10.64 % over 2024–2030.
• Among product segments, reagents & kits accounted for the largest share and are expected to grow at a 10.25 % CAGR during the forecast period.
• Looking at cell types, the stem cell segment captured 39.46 % of the market in 2023.
• On the technology front, microfluidics‐based techniques dominated in 2023.

Market Size & Forecast

• 2023 market size: USD 1.83 billion
• 2030 projected market: USD 3.46 billion
• Expected CAGR (2024–2030): 9.71 %
• North America will remain the largest regional market in 2023, while Asia Pacific leads in growth rate

Rare cells—such as circulating tumor cells (CTCs), stem cells, and fetal cells—are indispensable for early disease detection, monitoring treatment progression, and enabling personalized therapies. The rare cell isolation market comprises a variety of techniques and tools aimed at isolating these cells from biological samples like blood or tissue. Continuous technological innovation is enhancing the efficiency, accuracy, and throughput of isolation methods. To remain competitive, firms are integrating analysis and isolation into unified platforms and leveraging next-generation sequencing (NGS) and digital PCR to extract in-depth insights from isolated cells. Recent launches, such as the LeviCell EOS System by one firm and the CyteFinder II platform by another, underscore this drive toward more capable, combined systems.

Order a free sample PDF of the Rare Cell Isolation Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

The competitive landscape is marked by a moderate level of consolidation and significant investment in R&D and strategic collaborations. Firms are actively launching new solutions, expanding their portfolios, entering licensing or regional partnerships, and optimizing their technologies to serve both research and clinical settings. Regulatory and ethical oversight plays a critical role, shaping product development and adoption in diverse regions.

Key Companies

• Miltenyi Biotec
• Thermo Fisher Scientific, Inc.
• Danaher
• QIAGEN N.V.
• Bio-techne
• STEMCELL Technologies
• CELLENION
• RareCyte
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.

Recent notable developments include:

• Introduction of enhanced rare cell and CTC enrichment slides by one company in June 2024
• Launch of validated antibodies for rare cell enumeration in March 2024
• A partnership established in February 2024 between Akadeum Life Sciences and NanoCellect Biomedical to optimize rare cell workflows

Conclusion

Over the period from 2024 to 2030, the rare cell isolation market is poised for robust growth, nearly doubling in value. Growth will be fueled by technological advancements, growing interest in personalized medicine, and increasing prevalence of chronic diseases. While North America will continue to dominate in absolute terms, Asia Pacific is expected to outpace other regions in terms of growth rate. Major players in the industry are investing heavily in innovation and strategic collaborations to strengthen their position in this expanding market.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.